WYSO3h
What's happening with the anti-HIV program PEPFAR? It depends whom you ask
The President's Emergency Plan for AIDS Relief has been the subject of a series of presidential orders and memos that have ...
Too Old to Operate13h
PrEP Use Doubles Over 3 Years, but Uneven Access Persists
Despite an improved HIV PrEP-to-need ratio from 2018 to 2021, PrEP use relative to need was lower in certain populations, ...
STAT1d
Gilead’s short-term win threatens the future of pharmaceutical public-private partnerships
The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...
pharmaphorum1d
FDA okays ViiV's Apretude as first injectable for HIV PrEP
The FDA said that PrEP – used to protect at-risk people such as an HIV-negative individual with ... which suggests it is expecting high demand for the injectable alternative.
FiercePharma1d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
USA Today8d
The Supreme Court may hinder access to this HIV prevention, gay sex drug. Why?
PrEP became available in 2012, and so with it the freedom to have sex without fear of contracting HIV. But that doesn't mean everyone's on board. Those who are against PrEP believe that it ...
BioSpace1d
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.